PFM Health Sciences’s Lantheus LNTH Stock Holding History

PFM Health Sciences’s Portfolio LNTH Stock Details LNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-372,761	Closed	-$25.9M	–	73
2023 Q3	$25.9M	Buy	+372,761	New	+$27.3M	1.22%	36

Other funds holding LNTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PFM Health Sciences's LNTH Position: Q4 2023 in Review

PFM Health Sciences sold out of Lantheus (LNTH) in Q4 2023, closing a stake of 372,761 shares — an estimated $25.9M sold.

PFM Health Sciences first reported a position in LNTH in Q3 2023 and held it in 1 quarter. The position peaked at $25.9M in Q3 2023. 401 funds tracked by Wall St. Rank hold LNTH as of Q4 2023.

PFM Health Sciences reported no remaining Lantheus position as of Q4 2023 after selling out during the quarter.
PFM Health Sciences sold 372,761 Lantheus shares in Q4 2023, an estimated $25.9M.
PFM Health Sciences first reported a position in Lantheus in Q3 2023 and held it in 1 quarter.
PFM Health Sciences's Lantheus position peaked at $25.9M in Q3 2023.
401 funds tracked by Wall St. Rank held Lantheus as of Q4 2023.

Based on PFM Health Sciences's 13F filing for Q4 2023, filed 14 Feb 2024.